|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Short-term clinical outcomes of laparoscopic vs open rectal excision for rectal cancer: A systematic review and metaanalysis显示文摘AIM To review evidence on the short-term clinical outcomes of laparoscopic(LRR) vs open rectal resection(ORR) for rectal cancer.METHODS A systematic literature search was performed using Cochrane Central Register, MEDLINE, EMBASE, Scopus, Open Grey and Clinical Trials.gov register for randomized clinical trials(RCTs) comparing LRR vs ORR for rectal cancer and reporting short-term clinical outcomes. Articles published in English from January 1, 1995 to June, 30 2016 that met the selection criteria were retrieved and reviewed. The Preferred Reporting Items for Systematic reviews and Meta-Analysis(PRISMA) statements checklist for reporting a systematic review was followed. Random-effect models were used to estimate mean differences and risk ratios. The robustness and heterogeneity of the results were explored by performing sensitivity analyses. The pooledeffect was considered significant when P < 0.05.RESULTS Overall, 14 RCTs were included. No differences were found in postoperative mortality(P = 0.19) and morbidity(P = 0.75) rates. The mean operative time was 36.67 min longer(95%CI: 27.22-46.11, P < 0.00001), the mean estimated blood loss was 88.80 ml lower(95%CI:-117.25 to-60.34, P < 0.00001), and the mean incision length was 11.17 cm smaller(95%CI:-13.88 to-8.47, P < 0.00001) for LRR than ORR. These results were confirmed by sensitivity analyses that focused on the four major RCTs. The mean length of hospital stay was 1.71 d shorter(95%CI:-2.84 to-0.58, P < 0.003) for LRR than ORR. Similarly, bowel recovery(i.e., day of the first bowel movement) was 0.68 d shorter(95%CI:-1.00 to-0.36, P < 0.00001) for LRR. The sensitivity analysis did not confirm a significant difference between LRR and ORR for these latter two parameters. The overall quality of the evidence was rated as high. CONCLUSION LRR is associated with lesser blood loss, smaller incision length, and longer operative times compared to ORR. No differences are observed for postoperative morbidity and mortality. | Aleix Martínez-Pérez Maria Clotilde Carra Francesco Brunetti Nicola de'Angelis | 2017 | World Journal of Gastroenterology2017，23，44： | 33 |
| 2 | New approaches in angiogenic targeting for colorectal cancer显示文摘Colorectal carcinoma (CRC) is one of the leading causes of cancer death worldwide. In the last decade, the addition of irinotecan and oxaliplatin to standard fluorouracil-based chemotherapy regimens have set the new benchmark of survival for patients with metastatic CRC at approximately 20 mo. Despite these advances in the management of CRC, there is a strong medical need for more effective and well-tolerated therapies. The dependence of tumor growth and metastasis on blood vessels makes angiogenesis a rational target for therapy. One of the major pathways involved in this process is the vascular endothelial growth factor (VEGF) and its receptors (VEGFR). In 2004, the first agent targeting angiogenesis, bevacizumab (BV), was approved as an adjunct to first-line cytotoxic treatment of metastatic CRC. The role of BV as part of adjuvant treatment and in combination with other targeted therapies is the subject of ongoing trials. However, BV is associated with an increase in the risk of arterial thromboembolic events, hypertension and gastrointestinal perforations and its use must be cautious. Novel VEGFR TK inhibitors with different ranges of nanomolar potencies, selectivities, and pharmacokinetic properties are entering phase Ⅲ trials for the treatment of cancer. Conversely, one of these novel agents, vatalanib, has been shown not to confer survival benefit in first and second-line treatment of advanced CRC. The basis of these findings is being extensively evaluated. Ongoing and new well-designed trials will define the optimal clinical application of the actual antiangiogenic agents, and, on the other hand, intensive efforts in basic research will identify new agents with different antiangiogenic approaches for the treatment of CRC. In this review we discuss and highlight current and future approaches in angiogenic targeting for CRC. | Aleix Prat Esther Casado Javier Cortés | 2007 | World Journal of Gastroenterology2007，13，44： | 6 |
| 3 | Robotic transanal total mesorectal excision:Is the future now?显示文摘Total mesorectal excision(TME)is the standard surgical treatment for the curative radical resection of rectal cancers.Minimally invasive TME has been gaining ground favored by the continuous technological advancements.New procedures,such as transanal TME(TaTME),have been introduced to overcome some technical limitations,especially in low rectal tumors,obese patients,and/or narrow pelvis.The earliest TaTME reports showed promising results when compared with the conventional laparoscopic TME.However,recent publications raised concerns regarding the high rates of anastomotic leaks or local recurrences observed in national series.Robotic TaTME(R-TaTME)has been proposed as a novel technique incorporating the potential benefits of a perineal dissection together with precise control of the distal margins,and also offers all those advantages provided by the robotic technology in terms of improved precision and dexterity.Encouraging short-term results have been reported for R-TaTME,but further studies are needed to assess the real role of the new technique in the long-term oncological or functional outcomes.The present review aims to provide a general overview of R-TaTME by analyzing the body of the available literature,with a special focus on the potential benefits,harms,and future perspectives for this novel approach. | Juan Carlos Sebastián-Tomás Aleix Martínez-Pérez Elías Martínez-López Nicola de'Angelis Marcos Gómez Ruiz Eduardo García-Granero | 2021 | World Journal of Gastrointestinal Surgery2021，13，8： | 2 |
| 4 | Curvature property of compact spacelike hypersurfaees in de Sitter space显示文摘 | ALEIX) J A | 2001 | Differential Geometry and its Applications2001，14，： | 1 |
| 5 | Biocompatibility of cellulosic and synthetic membranes assessed by leukocyte activation显示文摘 | Maria PH Ana MC Aleix C et a1 | 2004 | AmJ Nephrol2004，24，2： | 1 |
| 6 | Martinez,subclass discriminant analysis显示文摘 | Manli Zhu Aleix M | 2006 | IEEE Trans PAMI2006，26，8： | 1 |
| 7 | Biocompatibility of cellulosiec and synthetic membranes assessed by leukocyte activation显示文摘 | Maria RH Ana MC Aleix C | 2004 | Am J Nephro12004，24，2： | 1 |
| 8 | Robust motion estimation under varying illumination 显示文摘 | Kim Yeon-Ho Martinez Aleix Kak Avi | 2005 | Image and Vision Computing2005，23，4： | 1 |
| 9 | PCA versus LDA 显示文摘 | Aleix M Martinez Avinash C Kak | 2001 | IEEE Trans On Pattern Analysis and Machine Intelligence2001，23，2： | 1 |
| 10 | Membrane thickness and preparation temperature as key parameters for controlling the macrovoid structure of chiral activated membranes(CAM)显示文摘 | Aleix C Tania G Palet C | 2007 | J Membr Sci2007，287，1： | 1 |
| 11 | Reticulated platelets in uremic patients:effect of hemodialysis and continuous ambulatory peritoneal dialysis显示文摘 | Dolors T Joan CR Aleix C | 1995 | Am J Hemotol1995，50，： | 1 |
| 12 | PCA and LDA显示文摘 | Aleix M Martinez Avinash C Kak | 2001 | IEEE Trans Patten Analysis and Machine Intelligence2001，23，2： | 1 |
| 13 | Development of Ti-Mo alloys for biomedical applications: Microstructure and electrochemical characterization显示文摘 | OIAVE1RA N T ALEIX CARAM R A | 2007 | Materials Science and Engineering: A2007，452，： | 1 |
| 14 | PCA versus LDA显示文摘 | Martinez Aleix M Kak Avinash C | 2001 | IEEE Transactions on Pattern Analysis and Machine Intelligence2001，23，2： | 1 |
| 15 | Deconstructing the molecular portraits of breast cancer显示文摘 | Aleix Prat Charles M. Perou | 2010 | Molecular Oncology2010，，1： | 1 |
| 16 | Biocompatibility of cellulosic and synthetic membranes assessed by leukocyte activation 显示文摘 | Maria RH Ana MG Aleix C | 2004 | Am J Nephrol2004，24，： | 1 |
| 17 | Real-time fluorescence image-guided gastrointestinal oncologic surgery:Towards a new era显示文摘Technological improvements are crucial in the evolution of surgery.Real-time fluorescence-guided surgery(FGS)has spread worldwide,mainly because of its usefulness during the intraoperative decision-making processes.The success of any gastrointestinal oncologic resection is based on the anatomical identification of the primary tumor and its regional lymph nodes.FGS allows also to evaluate the blood perfusion at the gastrointestinal stumps after colorectal or esophageal resections.Therefore,a reduction on the anastomotic leak rates has been postulated as one of the foreseeable benefits provided by the use of FGS in these procedures.Although the use of fluorescence in lymph node detection was initially described in breast cancer surgery,the technique is currently applied in gastric or splenic flexure cancers,as they both present complex and variable lymphatic drainages.FGS allows also to perform intraoperative lymphograms or sentinel lymph node biopsies.New applications of FGS are being developed to assist in the detection of peritoneal metastases or in the evaluation of the tumor resection margins.The present review aims to provide a general overview of the current status of real-time FGS in gastrointestinal oncologic surgery.We put a special focus on the different applications of FGS,discussing the main findings and limitations found in the contemporary literature and also the promising near future applications. | Elías Martínez-López Aleix Martínez-Pérez Sergio Navarro-Martínez Juan Carlos Sebastián-Tomás Nicola de'Angelis Eduardo García-Granero | 2021 | World Journal of Gastrointestinal Oncology2021，13，9： | 1 |
| 18 | Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status显示文摘 | Aleix Prat Cristina Cruz Katherine A. Hoadley Orland Díez Charles M. Perou Judith Balma?a | 2014 | Breast Cancer Research and Treatment2014，，1： | 1 |
| 19 | PCA versus LDA显示文摘 | ALEIX M Martinez AVINASH C Kak | 2001 | IEEE Trans PAMI2001，23，2： | 1 |
| 20 | Robust motion estimation under varying illumination 显示文摘 | Yeon H K Aleix M M | 2005 | Image and Vision Computing2005，23，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员